NCT03175835

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

An Open-label, Multiple Dose, Fixed-sequence, 3-period Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the drug interaction between CKD-519 and rosuvastatin in healthy male subjects.

Detailed description

An open-label, multiple dose, fixed-sequence, 3-period study to evaluate the drug interaction between CKD-519 and rosuvastatin in healthy male subjects.

Conditions

• Dyslipidemias

Interventions

Type	Name	Description
DRUG	Rosuvastatin 20 mg	Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
DRUG	CKD-519 200 mg	Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
DRUG	Rosuvastatin 20 mg & CKD-519 200 mg	Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26

Timeline

• Start date: 2017-05-08
• Primary completion: 2017-06-19
• Completion: 2017-06-19
• First posted: 2017-06-05
• Last updated: 2017-07-07

Locations

1 site across 1 country: South Korea